Biorchestra Raises $45M in Series C Funding
- Biorchestra, a Daejeon, South Korea, and Cambridge, Massachusetts, USA-based RNA therapeutics company, raised $45M in Series C funding
- The company intends to use the funds to support the expansion of research and development activities and product pipeline, completion of GMP facility
- The company is an innovative biotech developing ribonucleic acid (RNA) based therapeutics
- The BMD is a therapeutic agent development platform that can control microRNAs that regulate multiple messenger RNAs (mRNAs) involved in pathological factors related to diseases
- The company has developed proprietary drug delivery system (BDDS™) for commercial drug development
- Delivering the ASO via intravenous injection route, they observed target microRNA knock-down efficacy not only in cortex but also deep brain such as hippocampus even striatum and spinal cord as well
